ArticleFrontiers in ophthalmology2026
A longitudinal analysis of myopia progression and its predictors in a Ghanaian clinical cohort.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the rate of myopia progression among a clinical cohort in Ghana. Methods: A retrospective analysis was conducted using electronic medical records (EMRs) of all patients attending a tertiary eye care center in Ghana. Annual refractive data were extracted from January 2021 to December 2023. Myopia was defined as a spherical equivalent refraction (SER) of ≤ -0.50 D in at least one eye. Myopia progression was assessed by calculating the annual change in SER between visits, with progression defined as an SER change of ≤ -0.50 D/year. Given the moderate inter-eye correlation in progression rates, both eyes were analyzed independently. Results: Of the 4,010 EMRs reviewed during the study period, 280 patients with myopia were identified. After applying the eligibility criteria, 231 patient records were included in the final analysis. The mean age of participants was 29.41 ± 14.92 years (range: 5-81 years), and the majority were female (60.6%; n = 140). The mean rate of myopia progression was -0.063 D/year in the right eye and -0.089 D/year in the left eye. Using a progression threshold of ≤ -0.50 D/year in at least one eye, 17.7% of participants were classified as progressors, while 82.3% were non-progressors. In multivariable regression analyses adjusted for sex, age remained a significant predictor of myopia progression in our cohort (B = -0.043, SE = 0.014, p = 0.001; AOR = 0.958, 95% CI: 0.933-0.983). Conclusion: In this clinical cohort, myopia progression was generally slow, with fewer than one in five patients meeting the criteria for significant progression. Older age was independently associated with a lower risk of progression, whereas sex showed no significant association. These findings indicate that myopia progression in this predominantly adult Ghanaian population is relatively modest compared with rates reported in younger populations, and identify age as a key determinant of progression in routine clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.